Site-specific methylation of SRSF2 P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome
Science Translational Medicine · 01.04.2026 · 18 (843)
DOI: 10.1126/scitranslmed.adv1065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 01.04.2026. Verfasst von Zi-Juan Li und 37 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China. Hauptthemen laut MEDLINE: Serine-Arginine Splicing Factors, Myelodysplastic Syndromes, Histone-Lysine N-Methyltransferase, Myeloid-Derived Suppressor Cells. Die Arbeit nennt 56 Literaturangaben. Gefördert von: NHLBI NIH HHS, NIA NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Patients with myelodysplastic syndrome (MDS) harboring SRSF2 (serine and arginine rich splicing factor 2) mutations exhibit poor prognosis and aberrant inflammatory activation, underscoring an urgent need for therapies. Here, we reveal that low messenger RNA expression of SETD2 ( SET domain containing 2 ) in hematopoietic stem and progenitor cells (HSPCs) from patients with MDS carrying SRSF2P95 mutations (SRSF2 P95-Mut MDS) correlates with adverse outcomes and increased inflammation. Multivariate analysis confirmed the correlation between low SETD2 expression and poor prognosis in patients with SRSF2 P95-Mut MDS. Furthermore, Setd2 loss in the Srsf2 P95H/+ mouse model resulted in lethal MDS with hyperinflammation and expansion of myeloid-derived suppressor cells (MDSCs). Mechanistically, SETD2 methylates SRSF2 P95H at lysine-17 and lysine-65 to inhibit aberrant splicing of CEACAM1-4 (isoforms of carcinoembryonic antigen cell adhesion molecule ), which enhances interleukin-1β (IL-1β) signaling through Slc7a11 (solute carrier family 7 member 11)–mediated cystine uptake, thereby promoting HSPC differentiation into MDSCs, establishing an IL-1β–driven immunosuppressive microenvironment. These findings identify the SRSF2 P95H K17 me1 K65 me2 –CEACAM1-4 signaling axis as a promising therapeutic target in SRSF2 P95-Mut MDS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 20…
- Department of Hematology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200025, China.
- Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.
- Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.
ORCID-Profile: Zi-Juan Li, Mu-Ying Zhao, Roujia Wang, Na Liu, Binhe Chang, Xi-Ya Li, Chun-Hui Xu, Ping Liu, Bing-Yi Chen, Shu-Bei Chen, Qi-Jing Li, Bu-Sheng Xue, Jia-Cheng Jin, Yuanliang Zhang, Robert Peter Gale, Jianfei Fu, Qun-Ling Zhang, Xiaoning Wang, Qiuhua Huang, Yan Liu, Jun Qin, Xueshi Ye, Jin Zhang, Sai-Juan Chen, Peng-Cheng He, Chun-Kang Chang, Xiao-Jian Sun, Lan Wang
Förderung
- NHLBI NIH HHS
- NIA NIH HHS
- NIDDK NIH HHS
- Shanghai Municipal Technology Innovation Center
- National Natural Science Foundation of China
- Ministry of Science and Technology of the People's Republic of China
- China National Postdoctoral Fellowship Program
Zitieren
APA
Li, Z. J., Zhao, M. Y., Wang, R., Liu, N., Hu, C. L., Chang, B., Hu, F., Li, X. Y., Xu, C. H., Liu, P., Chen, B. Y., Chen, S. B., Wang, Y., Li, Q. J., Xue, B. S., Deng, C., Chen, X., Ren, Y., Jia-Cheng Jin, …, & Wang, L. (2026). Site-specific methylation of SRSF2 P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome. Science Translational Medicine, 18(843). https://doi.org/10.1126/scitranslmed.adv1065
Vancouver
Li ZJ, Zhao MY, Wang R, Liu N, Hu CL, Chang B, et al. Site-specific methylation of SRSF2 P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome. Science Translational Medicine. 2026;18(843). doi:10.1126/scitranslmed.adv1065
BibTeX
@article{Li2026,
author = {Li, Zi-Juan and Zhao, Mu-Ying and Wang, Roujia and Liu, Na and Hu, Cheng-Long and Chang, Binhe and Hu, Fang and Li, Xi-Ya and Xu, Chun-Hui and Liu, Ping and Chen, Bing-Yi and Chen, Shu-Bei and Wang, Yong and Li, Qi-Jing and Xue, Bu-Sheng and Deng, Chuhan and Chen, Xinchi and Ren, Yiyi and Jia-Cheng Jin and Yan, Xiao and Zhang, Yuanliang and Gale, Robert Peter and Fu, Jianfei and Zhang, Qun-Ling and Wang, Xiaoning and Huang, Qiuhua and Liu, Yan and Qiu, Ju and Qin, Jun and Ye, Xueshi and Zhang, Jin and Liang, Yang and Chen, Zhu and Chen, Sai-Juan and He, Peng-Cheng and Chang, Chun-Kang and Sun, Xiao-Jian and Wang, Lan},
title = {Site-specific methylation of SRSF2 P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome},
journal = {Science Translational Medicine},
year = {2026},
volume = {18},
number = {843},
doi = {10.1126/scitranslmed.adv1065}
}
EUVIMED